Browse > Article
http://dx.doi.org/10.3345/kjp.2010.53.2.239

High-dose caspofungin salvage in a very-low-birth-weight infant with refractory candidemia  

Seo, Eun Sun (Department of Pediatics, Busan St. Mary's Medical Center)
Park, Geun Hwa (Department of Pediatics, Busan St. Mary's Medical Center)
Kim, Sung Mi (Department of Pediatics, Busan St. Mary's Medical Center)
Jung, Hye An (Department of Radiology, Busan St. Mary's Medical Center)
Kim, Byoung Kuk (Department of clinical pathology, Busan St. Mary's Medical Center)
Publication Information
Clinical and Experimental Pediatrics / v.53, no.2, 2010 , pp. 239-243 More about this Journal
Abstract
Candidiasis is one of the most common causes of late-onset infection among very-low-birth-weight infants (VLBW) in most neonatal intensive care units and is associated with significant morbidity and mortality. Standard therapy consists of the administration of amphotericin B, amphotericin B complex, and fluconazole. In many cases, candidiasis is not easily eradicated, despite the administration of these drugs. We report our experience of the addition of high-dose caspofungin to the conventional antifungal drugs in a VLBW infant with refractory candidemia.
Keywords
Candidiasis; Caspofungin; Infant; Very low birth weight;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Chapman R. Prevention and treatment of candida infection in neonates. Semin Perinatol 2007;31:39-46   DOI   PUBMED   ScienceOn
2 Noyola DE, Fernandez M, Moylett EH, Baker CJ. Ophthalmologic, visceral, and cardiac involvement in neonates with candidemia. Clin Infect Dis 2001;32:1018-23   DOI   ScienceOn
3 Smith PB, Steinbach WJ, Cotten CM. Caspofungin for the treatment of azole resistant candidemia in a premature infant. J Perinatol 2007;27:127-9   DOI   ScienceOn
4 Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991;91(3B):72S-75S   PUBMED
5 Walsh TJ, Hiemenz JW, Seibel NL. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-96   DOI   ScienceOn
6 Denning DW. Echinocandin antifungal drugs. Lancet 2003;362:1142-51   DOI   ScienceOn
7 Clancy CJ, Nguyen MH. Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from multicenter prospective study of candidemia. Antimicrob Agents Chemother 1999;43:1289-90   PUBMED   ScienceOn
8 Bross J, Talbot GH, Maislin G, Hurwitz S, Storm BL. Risk factors for nosocomial candidemia: a case control study in adults without leukemia. Am J Med 1989;87:614-20   DOI   ScienceOn
9 Yalaz M, Akisu M, Hilmioglu S, Calkavur S, Cakmak B, Kultursay N, et al. Successful caspofungin treatment of multidrug resistant Candida parapsilosis septicaemia in an extremely low birth weight neonate. Mycoses 2006;49:242-5   DOI   ScienceOn
10 Odio CM, Araya R, Pinto LE, Castro CE, Vasquez S, Alfro B, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004;23:1093-7
11 Walsh TJ, Adamson PC, Seibel NL, Flynn PM, Neely MN, Schwartz C, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005;49:4536-45   DOI   ScienceOn
12 Keating GM, Jarvis B. Caspofungin. Drugs 2001;61:1121-9   DOI   ScienceOn
13 Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patients: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989;11:379-90   DOI   PUBMED
14 Wey SB, Motomi M, Pfaller MA, Woolson RF, Wenzel RP. Risk factor for hospital acquired candidemia: a matched casecontrol study. Arch Intern Med 1989;149:2349-53   DOI   ScienceOn
15 Arathoon EG. Clinical efficacy of echinocandin antifungals. Curr Opin Infect Dis 2001;14:685-91   PUBMED   ScienceOn
16 Kartsonis N, Killar J, Mixson L, Hoe CM, Sable C, Bartizal K. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: Relationship of MIC to treatment Outcome. Antimicrob Agents Chemother 2005;49;3616-23   DOI   ScienceOn
17 Stamos JK, Rowley AH. Candidemia in a pediatric population. Clin Infect Dis 1995;20:571-5   PUBMED   ScienceOn
18 Wey SB, Motomi M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1998;148:2642-7   DOI   ScienceOn
19 Tawawa S, Ikeda F, Maki K, Morishita Y, Otomo K, Teratani N, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicro Agents Chemother 2000;44:57-62   DOI   ScienceOn
20 Villanueva A, Gotuzzo E, Arathoon EG. A randomized double- blind study of caspofugin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001;33:1529-35   DOI   ScienceOn
21 Steinbach WJ, Benjamin DK. New antifungal agents under development in children and neonates. Curr Opin Infect Dis 2005;18:484-9   DOI   ScienceOn
22 Natarajan G, Lulic-Botica M. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005;25:770-7   DOI   ScienceOn